Cargando…
Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism
Duchenne muscular dystrophy (DMD) is the most common inherited muscle disorder that causes severe disability and death of young men. This disease is characterized by progressive muscle degeneration aggravated by sterile inflammation and is also associated with cognitive impairment and low bone densi...
Autores principales: | Al-Khalidi, Rasha, Panicucci, Chiara, Cox, Paul, Chira, Natalia, Róg, Justyna, Young, Christopher N. J., McGeehan, Rhiannon E., Ambati, Kameshwari, Ambati, Jayakrishna, Zabłocki, Krzysztof, Gazzerro, Elisabetta, Arkle, Stephen, Bruno, Claudio, Górecki, Dariusz C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5896059/ https://www.ncbi.nlm.nih.gov/pubmed/29642926 http://dx.doi.org/10.1186/s40478-018-0530-4 |
Ejemplares similares
-
P2RX7 Purinoceptor: A Therapeutic Target for Ameliorating the Symptoms of Duchenne Muscular Dystrophy
por: Sinadinos, Anthony, et al.
Publicado: (2015) -
P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles
por: Rumney, Robin M. H., et al.
Publicado: (2022) -
P2RX7 Purinoceptor as a Therapeutic Target—The Second Coming?
por: Young, Chris N. J., et al.
Publicado: (2018) -
Primary mouse myoblast metabotropic purinoceptor profiles and calcium signalling differ with their muscle origin and are altered in mdx dystrophinopathy
por: Róg, Justyna, et al.
Publicado: (2023) -
P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment
por: Young, Christopher N J, et al.
Publicado: (2012)